For research use only
| Cat No. | ABC-X0013C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The EML4-ALK (F1174L) BAF3 Cell Line supports research on resistance to ALK inhibitors and mechanisms of ALK-driven transformation in cancer.
The EML4 ALK (F1174L) BAF3 Cell Line is constructed by lentiviral-mediated stable integration of human EML4-ALK fusion carrying the F1174L activating mutation into BAF3 cells. This mutation occurs within the ALK kinase domain and contributes to increased oncogenicity and reduced inhibitor binding. Stable clones are maintained under antibiotic selection and confirmed by qRT-PCR.
Target
EML4-ALK is a constitutively active fusion protein in non-small cell lung cancer (NSCLC). The F1174L mutation enhances kinase activity and induces resistance to ALK inhibitors such as crizotinib. This model is suitable for studying ALK-driven oncogenesis and resistance mechanisms. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0013C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The EML4 ALK (F1174L) BAF3 Cell Line is ideal for drug resistance screening, functional validation of ALK inhibitors, and investigation of downstream signaling in ALK-mutant NSCLC. It supports the development of next-generation therapeutics overcoming ALK resistance mutations.